MiMedx Group (MDXG) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.10
- EPS estimate
- −$0.05
- EPS surprise
- −102.02%
- Revenue surprise
- +1.42%
- Revenue
- $64.4M
- Revenue estimate
- $63.5M
- Reported
- Jul 29, 2026
MiMedx reported Q2 2026 results on July 29, 2026. It posted a loss of $0.10 per share, wider than the expected $0.05 loss, a miss of 102.02%. Revenue was $64.4 million, 1.42% above the $63.5 million estimate. In Q2 2025, MiMedx earned $0.06 per share on revenue of $98.6 million, so revenue fell about 35% year over year.
The last two quarters broke a profitable run. After losses in all four quarters of 2022 and in Q1 2023, MiMedx broke even in Q2 2023 and earned a profit in every quarter from Q3 2023 through Q4 2025. Annual EPS was $0.32 in 2023, $0.28 in 2024 and $0.32 in 2025, while revenue grew from $321.5 million to $418.6 million. Revenue peaked here at $118.1 million in Q4 2025, then fell by half to $59.0 million in Q1 2026. MiMedx beat the EPS estimate in 13 of the last 20 quarters, but in only 4 of the last 8.
Q3 results came out between October 29 and November 2 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether the company returns to a profit.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 29, 2026 | −$0.05 | −$0.10 | −102.02% | $64.4M | SEC |
| Q1 2026 | Apr 29, 2026 | −$0.03 | −$0.07 | −178.88% | $59.0M | SEC |
| Q4 2025 | Feb 25, 2026 | $0.09 | $0.10 | +13.25% | $118.1M | SEC |
| Q3 2025 | Oct 29, 2025 | $0.08 | $0.11 | +40.66% | $113.7M | SEC |
| Q2 2025 | Jul 30, 2025 | $0.05 | $0.06 | +14.29% | $98.6M | SEC |
| Q1 2025 | Apr 30, 2025 | $0.05 | $0.05 | −7.41% | $88.2M | SEC |
| Q4 2024 | Feb 26, 2025 | $0.07 | $0.05 | −30.56% | $92.9M | SEC |
| Q3 2024 | Oct 30, 2024 | $0.04 | $0.05 | +13.64% | $84.1M | SEC |
| Q2 2024 | Jul 31, 2024 | $0.08 | $0.12 | +60.00% | $87.2M | SEC |
| Q1 2024 | Apr 30, 2024 | $0.05 | $0.06 | +33.33% | $84.7M | SEC |
| Q4 2023 | Feb 28, 2024 | $0.07 | $0.32 | +344.44% | $86.8M | SEC |
| Q3 2023 | Oct 30, 2023 | $0.05 | $0.06 | +30.43% | $81.7M | SEC |
| Q2 2023 | Aug 1, 2023 | −$0.02 | $0.00 | +100.00% | $81.3M | SEC |
| Q1 2023 | May 2, 2023 | −$0.09 | −$0.06 | +30.80% | $71.7M | SEC |
| Q4 2022 | Feb 28, 2023 | −$0.04 | −$0.02 | +50.00% | $74.4M | SEC |
| Q3 2022 | Nov 2, 2022 | −$0.08 | −$0.09 | −16.13% | $67.7M | SEC |
| Q2 2022 | Aug 2, 2022 | −$0.06 | −$0.11 | −94.00% | $66.9M | SEC |
| Q1 2022 | May 3, 2022 | −$0.10 | −$0.11 | −10.00% | $58.9M | SEC |
| Q4 2021 | Feb 28, 2022 | −$0.03 | $0.01 | +130.03% | $67.4M | SEC |
| Q3 2021 | Nov 2, 2021 | −$0.08 | $0.02 | +128.88% | $63.1M | SEC |
Quarterly revenue
Frequently asked questions
When did MiMedx Group (MDXG) last report earnings?
MiMedx Group last reported on Jul 29, 2026, covering fiscal Q2 2026.
Did MDXG beat earnings estimates?
No. MiMedx Group reported EPS of −$0.10 for Q2 2026 against a −$0.05 estimate — a 102.02% miss.
How much revenue did MDXG report last quarter?
MiMedx Group reported $64.4M in revenue for Q2 2026, against a consensus estimate of $63.5M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.